Entocort EC and Ortikos:
Entocort EC and Ortikos:
Uceris:
Tarpeyo:
Contraindicated in:
Use Cautiously in:
CV: edema, hypertension, palpitations, tachycardia.
Derm: acne, easy bruising, hirsutism, alopecia, dermatitis, eczema, flushing, striae, sweating.
EENT: abnormal vision, conjunctivitis.
Endo: ADRENAL SUPPRESSION, hypokalemia.
GI: nausea, abdominal pain, dyspepsia, flatulence, vomiting.
GU: dysuria, irregular menses, nocturia, urinary frequency.
Hemat: leukocytosis.
Metab: weight gain.
MS: back pain, cramps, myalgia.
Neuro: hyperkinesia, paresthesia, tremor, headache, agitation, confusion, dizziness, drowsiness, fatigue, ↑ appetite, insomnia, malaise, nervousness, vertigo.
Resp: bronchitis, dyspnea.
Drug-Drug:
Drug-Natural Products:
Drug-Food:
(Generic available)
Treatment of Active Crohn's Disease (Entocort EC and Ortikos)
Hepatic Impairment
Maintenance of Remission of Crohn's Disease (Entocort EC and Ortikos)
Hepatic Impairment
Induction of Remission of Ulcerative Colitis (Uceris)
Reduction in Proteinuria Associated with Primary Immunoglobulin A Nephropathy (Tarpeyo)
Therapeutic Classification: gastrointestinal anti-inflammatories
Pharmacologic Classification: corticosteroids
Absorption: Well absorbed following oral administration (921% bioavailability).
Distribution: Widely distributed to extravascular tissues; enters breast milk.
Protein Binding: 8590%.
Metabolism/Excretion: Rapidly and extensively metabolized during first pass hepatic metabolism by the CYP3A4 enzyme system to inactive metabolites which are excreted in urine and feces.
Half-life: 2.03.6 hr; Tarpeyo 56.8 hr.
(improvement in symptoms of Crohns disease or induction of remission of ulcerative colitis)
ROUTE | ONSET | PEAK | DURATION |
PO | unknown | unknown | unknown |
NDC Code*